Cargando…

Use of health technology assessment in drug reimbursement decisions in China

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2023
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286107/ https://www.ncbi.nlm.nih.gov/pubmed/37348901 http://dx.doi.org/10.1136/bmj.p1427

Ejemplares similares

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Conflict of interest in Health Technology Assessment decisions: case law in France and impact on reimbursement decisions
por: Frybourg, Sandrine, et al.
Publicado: (2015)

Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies
por: Elvira, David, et al.
Publicado: (2021)

Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy
por: Chen, Yingyao, et al.
Publicado: (2023)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Using multicriteria decision analysis during drug development to predict reimbursement decisions
por: Williams, Paul, et al.
Publicado: (2014)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

How health technology reassessment can support disinvestment in China’s national drug reimbursement list
por: Shi, Lizheng, et al.
Publicado: (2023)

Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019)

Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
por: Drummond, Michael, et al.
Publicado: (2010)

Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
por: Chauca Strand, G., et al.
Publicado: (2022)

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
por: Ling, Kexin, et al.
Publicado: (2022)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

Correction to: A pain relieving reimbursement program? Effects of a value-based reimbursement program on patient reported outcome measures
por: Eriksson, Thérèse, et al.
Publicado: (2020)

Correction: Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis
Publicado: (2022)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations
por: Binder, Louise, et al.
Publicado: (2022)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives
por: Chachoua, Lylia, et al.
Publicado: (2020)

The Potential for Early Health Economic Modelling in Health Technology Assessment and Reimbursement Decision-Making Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modeling"
por: Kim, Hansoo, et al.
Publicado: (2020)

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework
por: Paulden, Mike, et al.
Publicado: (2014)

Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
por: Enzing, Joost J., et al.
Publicado: (2022)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Drug pricing and reimbursement information management: processes and decision making in the global economy
por: Tsourougiannis, Dimitrios
Publicado: (2017)

Correction to: Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries
por: Fontrier, Anna-Maria, et al.
Publicado: (2022)

Correction: Comparing Maternal Services Utilization and Expense Reimbursement Before and After the Adjustment of the New Rural Cooperative Medical Scheme Policy in Rural China
por: You, Hua, et al.
Publicado: (2017)

Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion
por: Iskrov, Georgi, et al.
Publicado: (2016)

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
por: van Harten, WH, et al.
Publicado: (2016)

“Budget Impact Analyses”: A Practical Policy Making Tool for Drug Reimbursement Decisions
por: Jamshidi, Hamid Reza, et al.
Publicado: (2014)

Cancer therapy: reimbursement of new therapeutic technologies.
por: Williams, H. M.
Publicado: (1992)

Correction: How does it affect service delivery under the National Health Insurance Scheme in Ghana? Health providers and insurance managers perspective on submission and reimbursement of claims
por: Akweongo, Patricia, et al.
Publicado: (2021)

The evolution of Taiwan’s National Health Insurance drug reimbursement scheme
por: Hsu, Jason C, et al.
Publicado: (2015)

Assessment of Methodological Quality of Economic Evaluations in Belgian Drug Reimbursement Applications
por: Simoens, Steven
Publicado: (2013)

Correction to: Impact assessment of Iran’s health technology assessment programme
por: Yazdizadeh, Bahareh, et al.
Publicado: (2018)

Using economic evaluations to support acupuncture reimbursement decisions: current evidence and gaps
por: Li, Hongchao, et al.
Publicado: (2022)

The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
por: Tsai, Hsin-Yi, et al.
Publicado: (2022)

Informed decision‐making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments
por: Weir, Christopher J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_he3r0v70661khaeboqu77f1unu